Cosmo Pharmaceuticals N.V. (0RGI.L)

46.25 -0.10 (-0.22%) As of 03:11PM BST. Market open.

Cosmo Pharmaceuticals N.V.

Riverside II
Sir John Rogerson’s Quay
Dublin 2
Ireland
353 1 817 0370
https://www.cosmopharma.com

Sector(s): 
Industry: 
Full-time employees: 290

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Mauro Severino Ajani	Founder & Exec. Chairman	420.79k	N/A	1955
Mr. Alessandro E. Della Cha LL.M	CEO & Exec. Director	637.65k	N/A	1963
Mr. Ngo Dinh Nhan	Head of R&D - AI & Biomedical IT	N/A	N/A	1979
Mr. Giulio Evangelisti	Head of Production, AI & Biomedical IT	N/A	N/A	1970
Mr. Niall Donnelly	Chief Financial Officer	N/A	N/A	1972
Mr. Marco Lecchi	Chief Operating Officer	N/A	N/A	1964
Mr. Davide Malavasi	Qualified Person & Technical Director	N/A	N/A	1973
Mr. Luigi Longo	Chief Scientific Officer	N/A	N/A	1979
Ms. Hazel Winchester	Head of Investor Relations	N/A	N/A	1971
Mr. Biagio Vigano	Chief People Officer	N/A	N/A	1974

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CHF.

Description

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy. The company also provides Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions; Aemcolo/Relafalk, a pharmaceutical product used for the treatment of traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth; and Winlevi, an androgen receptor inhibitor for acne vulgaris. In addition, it offers Clascoterone, an androgen receptor inhibitor that targets in the scalp and androgenetic alopecia; Rifamycin for irritable bowel syndrome with diarrhoea; ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent for procedural sedation; CB-03-10, an oral androgen receptor antagonist for treatment against solid tumors; CB-01-33 for bile acid diarrhea; and Qolotag, a single use enema formulation. The company has a license agreement with RedHill Biopharma Ltd.; and Acacia Pharma Group plc. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.

Corporate governance

Cosmo Pharmaceuticals N.V.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.